1
|
van Dyck CH, Mecca AP, O'Dell RS, Bartlett HH, Diepenbrock NG, Huang Y, Hamby ME, Grundman M, Catalano SM, Caggiano AO, Carson RE. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's disease. Alzheimers Res Ther 2024; 16:20. [PMID: 38273408 PMCID: PMC10809445 DOI: 10.1186/s13195-024-01382-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Accepted: 01/01/2024] [Indexed: 01/27/2024]
Abstract
BACKGROUND Effective, disease-modifying therapeutics for the treatment of Alzheimer's disease (AD) remain a large unmet need. Extensive evidence suggests that amyloid beta (Aβ) is central to AD pathophysiology, and Aβ oligomers are among the most toxic forms of Aβ. CT1812 is a novel brain penetrant sigma-2 receptor ligand that interferes with the binding of Aβ oligomers to neurons. Preclinical studies of CT1812 have demonstrated its ability to displace Aβ oligomers from neurons, restore synapses in cell cultures, and improve cognitive measures in mouse models of AD. CT1812 was found to be generally safe and well tolerated in a placebo-controlled phase 1 clinical trial in healthy volunteers and phase 1a/2 clinical trials in patients with mild to moderate dementia due to AD. The unique objective of this study was to incorporate synaptic positron emission tomography (PET) imaging as an outcome measure for CT1812 in AD patients. METHODS The present phase 1/2 study was a randomized, double-blind, placebo-controlled, parallel-group trial conducted in 23 participants with mild to moderate dementia due to AD to primarily evaluate the safety of CT1812 and secondarily its pharmacodynamic effects. Participants received either placebo or 100 mg or 300 mg per day of oral CT1812 for 24 weeks. Pharmacodynamic effects were assessed using the exploratory efficacy endpoints synaptic vesicle glycoprotein 2A (SV2A) PET, fluorodeoxyglucose (FDG) PET, volumetric MRI, cognitive clinical measures, as well as cerebrospinal fluid (CSF) biomarkers of AD pathology and synaptic degeneration. RESULTS No treatment differences relative to placebo were observed in the change from baseline at 24 weeks in either SV2A or FDG PET signal, the cognitive clinical rating scales, or in CSF biomarkers. Composite region volumetric MRI revealed a trend towards tissue preservation in participants treated with either dose of CT1812, and nominally significant differences with both doses of CT1812 compared to placebo were found in the pericentral, prefrontal, and hippocampal cortices. CT1812 was safe and well tolerated. CONCLUSIONS The safety findings of this 24-week study and the observed changes on volumetric MRI with CT1812 support its further clinical development. TRIAL REGISTRATION The clinical trial described in this manuscript is registered at clinicaltrials.gov (NCT03493282).
Collapse
Affiliation(s)
- Christopher H van Dyck
- Alzheimer's Disease Research Unit, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
| | - Adam P Mecca
- Alzheimer's Disease Research Unit, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
| | - Ryan S O'Dell
- Alzheimer's Disease Research Unit, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
| | - Hugh H Bartlett
- Alzheimer's Disease Research Unit, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
| | - Nina G Diepenbrock
- Alzheimer's Disease Research Unit, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
| | - Yiyun Huang
- Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT, USA
| | - Mary E Hamby
- Cognition Therapeutics Inc., Pittsburgh, PA, USA
| | - Michael Grundman
- Global R&D Partners, LLC, San Diego, CA, USA
- Department of Neurosciences, University of California, San Diego, USA
| | | | | | - Richard E Carson
- Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT, USA
| |
Collapse
|
2
|
Mecca AP, O'Dell RS, Sharp ES, Banks ER, Bartlett HH, Zhao W, Lipior S, Diepenbrock NG, Chen M, Naganawa M, Toyonaga T, Nabulsi NB, Vander Wyk BC, Arnsten AFT, Huang Y, Carson RE, van Dyck CH. Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [ 11 C]UCB-J. Alzheimers Dement 2022; 18:2527-2536. [PMID: 35174954 PMCID: PMC9381645 DOI: 10.1002/alz.12582] [Citation(s) in RCA: 51] [Impact Index Per Article: 25.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2021] [Revised: 11/23/2021] [Accepted: 12/12/2021] [Indexed: 01/31/2023]
Abstract
INTRODUCTION For 30 years synapse loss has been referred to as the major pathological correlate of cognitive impairment in Alzheimer's disease (AD). However, this statement is based on remarkably few patients studied by autopsy or biopsy. With the recent advent of synaptic vesicle glycoprotein 2A (SV2A) positron emission tomography (PET) imaging, we have begun to evaluate the consequences of synaptic alterations in vivo. METHODS We examined the relationship between synaptic density measured by [11 C]UCB-J PET and neuropsychological test performance in 45 participants with early AD. RESULTS Global synaptic density showed a significant positive association with global cognition and performance on five individual cognitive domains in participants with early AD. Synaptic density was a stronger predictor of cognitive performance than gray matter volume. CONCLUSION These results confirm neuropathologic studies demonstrating a significant association between synaptic density and cognitive performance, and suggest that this correlation extends to the early stages of AD.
Collapse
Affiliation(s)
- Adam P. Mecca
- Alzheimer's Disease Research UnitYale University School of MedicineNew HavenConnecticutUSA
- Department of PsychiatryYale University School of MedicineNew HavenConnecticutUSA
| | - Ryan S. O'Dell
- Alzheimer's Disease Research UnitYale University School of MedicineNew HavenConnecticutUSA
- Department of PsychiatryYale University School of MedicineNew HavenConnecticutUSA
| | - Emily S. Sharp
- Alzheimer's Disease Research UnitYale University School of MedicineNew HavenConnecticutUSA
- Department of NeurologyYale University School of MedicineNew HavenConnecticutUSA
| | - Emmie R. Banks
- Alzheimer's Disease Research UnitYale University School of MedicineNew HavenConnecticutUSA
- Department of PsychiatryYale University School of MedicineNew HavenConnecticutUSA
| | - Hugh H. Bartlett
- Alzheimer's Disease Research UnitYale University School of MedicineNew HavenConnecticutUSA
- Department of PsychiatryYale University School of MedicineNew HavenConnecticutUSA
| | - Wenzhen Zhao
- Alzheimer's Disease Research UnitYale University School of MedicineNew HavenConnecticutUSA
- Department of PsychiatryYale University School of MedicineNew HavenConnecticutUSA
| | - Sylwia Lipior
- Alzheimer's Disease Research UnitYale University School of MedicineNew HavenConnecticutUSA
- Department of PsychiatryYale University School of MedicineNew HavenConnecticutUSA
| | - Nina G. Diepenbrock
- Alzheimer's Disease Research UnitYale University School of MedicineNew HavenConnecticutUSA
- Department of PsychiatryYale University School of MedicineNew HavenConnecticutUSA
| | - Ming‐Kai Chen
- Department of Radiology and Biomedical ImagingYale University School of MedicineNew HavenConnecticutUSA
| | - Mika Naganawa
- Department of Radiology and Biomedical ImagingYale University School of MedicineNew HavenConnecticutUSA
| | - Takuya Toyonaga
- Department of Radiology and Biomedical ImagingYale University School of MedicineNew HavenConnecticutUSA
| | - Nabeel B. Nabulsi
- Department of Radiology and Biomedical ImagingYale University School of MedicineNew HavenConnecticutUSA
| | | | - Amy F. T. Arnsten
- Alzheimer's Disease Research UnitYale University School of MedicineNew HavenConnecticutUSA
- Department of NeuroscienceYale University School of MedicineNew HavenConnecticutUSA
| | - Yiyun Huang
- Program on AgingYale University School of MedicineNew HavenConnecticutUSA
| | - Richard E. Carson
- Program on AgingYale University School of MedicineNew HavenConnecticutUSA
| | - Christopher H. van Dyck
- Alzheimer's Disease Research UnitYale University School of MedicineNew HavenConnecticutUSA
- Department of PsychiatryYale University School of MedicineNew HavenConnecticutUSA
- Department of NeurologyYale University School of MedicineNew HavenConnecticutUSA
- Department of NeuroscienceYale University School of MedicineNew HavenConnecticutUSA
| |
Collapse
|
3
|
Young JJ, Park H, Par‐Young J, Bartlett HH, Kim HS, Shin MS, You S, Kim MH, Allore HG, Mecca AP, Kang I. Investigating a CD8
+
T cell age‐associated gene signature in Alzheimer's disease. Alzheimers Dement 2022. [DOI: 10.1002/alz.064384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | | | | | | | - Hye Sun Kim
- Yale School of Public Health New Haven CT USA
| | | | | | | | - Heather G. Allore
- Yale School of Medicine New Haven CT USA
- Yale School of Public Health New Haven CT USA
| | | | - Insoo Kang
- Yale School of Medicine New Haven CT USA
| |
Collapse
|
4
|
van Dyck CH, Sharp E, O'Dell RS, Banks ER, Bartlett HH, Chen M, Naganawa M, Toyonaga T, Harris JE, Ni GS, Zhao W, Nabulsi NB, Wyk BCV, Huang Y, Arnsten AFT, Carson RE, Mecca AP. Synaptic density is associated with cognitive performance in Alzheimer’s disease: A PET imaging study with [11C]UCB‐J. Alzheimers Dement 2021. [DOI: 10.1002/alz.054213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
5
|
O’Dell RS, Mecca AP, Chen MK, Naganawa M, Toyonaga T, Lu Y, Godek TA, Harris JE, Bartlett HH, Banks ER, Kominek VL, Zhao W, Nabulsi NB, Ropchan J, Ye Y, Vander Wyk BC, Huang Y, Arnsten AFT, Carson RE, van Dyck CH. Association of Aβ deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [ 11C]UCB-J. Alzheimers Res Ther 2021; 13:11. [PMID: 33402201 PMCID: PMC7786921 DOI: 10.1186/s13195-020-00742-y] [Citation(s) in RCA: 46] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2020] [Accepted: 12/07/2020] [Indexed: 01/18/2023]
Abstract
BACKGROUND Attempts to associate amyloid-β (Aβ) pathogenesis with synaptic loss in Alzheimer's disease (AD) have thus far been limited to small numbers of postmortem studies. Aβ plaque burden is not well-correlated with indices of clinical severity or neurodegeneration-at least in the dementia stage-as deposition of Aβ reaches a ceiling. In this study, we examined in vivo the association between fibrillar Aβ deposition and synaptic density in early AD using positron emission tomography (PET). We hypothesized that global Aβ deposition would be more strongly inversely associated with hippocampal synaptic density in participants with amnestic mild cognitive impairment (aMCI; a stage of continued Aβ accumulation) compared to those with dementia (a stage of relative Aβ plateau). METHODS We measured SV2A binding ([11C]UCB-J) and Aβ deposition ([11C]PiB) in 14 participants with aMCI due to AD and 24 participants with mild AD dementia. Distribution volume ratios (DVR) with a cerebellar reference region were calculated for both tracers to investigate the association between global Aβ deposition and SV2A binding in hippocampus. Exploratory analyses examined correlations between both global and regional Aβ deposition and SV2A binding across a broad range of brain regions using both ROI- and surface-based approaches. RESULTS We observed a significant inverse association between global Aβ deposition and hippocampal SV2A binding in participants with aMCI (r = - 0.55, P = 0.04), but not mild dementia (r = 0.05, P = 0.82; difference statistically significant by Fisher z = - 1.80, P = 0.04). Exploratory analyses across other ROIs and whole brain analyses demonstrated no broad or consistent associations between global Aβ deposition and regional SV2A binding in either diagnostic group. ROI-based analyses of the association between regional Aβ deposition and SV2A binding also revealed no consistent pattern but suggested a "paradoxical" positive association between local Aβ deposition and SV2A binding in the hippocampus. CONCLUSIONS Our findings lend support to a model in which fibrillar Aβ is still accumulating in the early stages of clinical disease but approaching a relative plateau, a point at which Aβ may uncouple from neurodegenerative processes including synaptic loss. Future research should investigate the relationship between Aβ deposition and synaptic loss in larger cohorts beginning preclinically and followed longitudinally in conjunction with other biomarkers.
Collapse
Affiliation(s)
- Ryan S. O’Dell
- Alzheimer’s Disease Research Unit, Yale University School of Medicine, One Church Street, 8th Floor, New Haven, CT 06510 USA
- Department of Psychiatry, Yale University School of Medicine, 300 George Street, New Haven, CT 06510 USA
| | - Adam P. Mecca
- Alzheimer’s Disease Research Unit, Yale University School of Medicine, One Church Street, 8th Floor, New Haven, CT 06510 USA
- Department of Psychiatry, Yale University School of Medicine, 300 George Street, New Haven, CT 06510 USA
| | - Ming-Kai Chen
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, P.O. Box 208048, New Haven, CT 06520 USA
| | - Mika Naganawa
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, P.O. Box 208048, New Haven, CT 06520 USA
| | - Takuya Toyonaga
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, P.O. Box 208048, New Haven, CT 06520 USA
| | - Yihuan Lu
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, P.O. Box 208048, New Haven, CT 06520 USA
| | - Tyler A. Godek
- Alzheimer’s Disease Research Unit, Yale University School of Medicine, One Church Street, 8th Floor, New Haven, CT 06510 USA
- Department of Psychiatry, Yale University School of Medicine, 300 George Street, New Haven, CT 06510 USA
| | - Joanna E. Harris
- Alzheimer’s Disease Research Unit, Yale University School of Medicine, One Church Street, 8th Floor, New Haven, CT 06510 USA
- Department of Psychiatry, Yale University School of Medicine, 300 George Street, New Haven, CT 06510 USA
| | - Hugh H. Bartlett
- Alzheimer’s Disease Research Unit, Yale University School of Medicine, One Church Street, 8th Floor, New Haven, CT 06510 USA
- Department of Psychiatry, Yale University School of Medicine, 300 George Street, New Haven, CT 06510 USA
| | - Emmie R. Banks
- Alzheimer’s Disease Research Unit, Yale University School of Medicine, One Church Street, 8th Floor, New Haven, CT 06510 USA
- Department of Psychiatry, Yale University School of Medicine, 300 George Street, New Haven, CT 06510 USA
| | - Victoria L. Kominek
- Alzheimer’s Disease Research Unit, Yale University School of Medicine, One Church Street, 8th Floor, New Haven, CT 06510 USA
- Department of Psychiatry, Yale University School of Medicine, 300 George Street, New Haven, CT 06510 USA
| | - Wenzhen Zhao
- Alzheimer’s Disease Research Unit, Yale University School of Medicine, One Church Street, 8th Floor, New Haven, CT 06510 USA
- Department of Psychiatry, Yale University School of Medicine, 300 George Street, New Haven, CT 06510 USA
| | - Nabeel B. Nabulsi
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, P.O. Box 208048, New Haven, CT 06520 USA
| | - Jim Ropchan
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, P.O. Box 208048, New Haven, CT 06520 USA
| | - Yunpeng Ye
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, P.O. Box 208048, New Haven, CT 06520 USA
| | - Brent C. Vander Wyk
- Program on Aging, Yale University School of Medicine, P.O. Box 207900, New Haven, CT 06520 USA
| | - Yiyun Huang
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, P.O. Box 208048, New Haven, CT 06520 USA
| | - Amy F. T. Arnsten
- Department of Neuroscience, Yale University School of Medicine, P.O. Box 208001, New Haven, CT 06520 USA
| | - Richard E. Carson
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, P.O. Box 208048, New Haven, CT 06520 USA
| | - Christopher H. van Dyck
- Alzheimer’s Disease Research Unit, Yale University School of Medicine, One Church Street, 8th Floor, New Haven, CT 06510 USA
- Department of Psychiatry, Yale University School of Medicine, 300 George Street, New Haven, CT 06510 USA
- Department of Neuroscience, Yale University School of Medicine, P.O. Box 208001, New Haven, CT 06520 USA
- Department of Neurology, Yale University School of Medicine, P.O. Box 208018, New Haven, CT 06520 USA
| |
Collapse
|
6
|
Mecca AP, O'Dell RS, Chen M, Naganawa M, Toyonaga T, Godek TA, Harris JE, Bartlett HH, Zhao W, Gallezot J, Nabulsi NB, Ropchan JR, Ye Y, Wyk BCV, Arnsten AF, Huang Y, Carson RE, van Dyck CH. In vivo measurement of widespread synaptic loss and associated tau accumulation in early Alzheimer’s disease. Alzheimers Dement 2020. [DOI: 10.1002/alz.037791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | - Yunpeng Ye
- Yale School of Medicine New Haven CT USA
| | | | | | | | | | | |
Collapse
|
7
|
O'Dell RS, Mecca AP, Chen M, Godek TA, Harris JE, Bartlett HH, Banks ER, Kominek VL, Zhao W, Naganawa M, Toyonaga T, Lu Y, Nabulsi NB, Ropchan JR, Ye Y, Vander Wyk BC, Varma P, Arnsten AF, Huang Y, Carson RE, van Dyck CH. Association between cerebral amyloid accumulation and synaptic density in Alzheimer’s disease: A multitracer PET study. Alzheimers Dement 2020. [DOI: 10.1002/alz.043631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Yihuan Lu
- Yale School of Medicine New Haven CT USA
| | | | | | - Yunpeng Ye
- Yale School of Medicine New Haven CT USA
| | | | | | | | | | | | | |
Collapse
|
8
|
Mecca AP, Ashton NJ, Chen M, O'Dell RS, Naganawa M, Toyonaga T, Harris JE, Bartlett HH, Banks ER, Kominek VL, Nabulsi NB, Najafzadeh S, Wyk BCV, Brinkmalm A, Kvartsberg H, Schöll M, Arnsten AF, Huang Y, Blennow K, Zetterberg H, Carson RE, van Dyck CH. Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimer’s disease. Alzheimers Dement 2020. [DOI: 10.1002/alz.044211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
9
|
Mecca AP, Chen MK, O'Dell RS, Naganawa M, Toyonaga T, Godek TA, Harris JE, Bartlett HH, Zhao W, Nabulsi NB, Wyk BCV, Varma P, Arnsten AFT, Huang Y, Carson RE, van Dyck CH. In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET. Alzheimers Dement 2020; 16:974-982. [PMID: 32400950 PMCID: PMC7383876 DOI: 10.1002/alz.12097] [Citation(s) in RCA: 155] [Impact Index Per Article: 38.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2019] [Revised: 02/18/2020] [Accepted: 03/02/2020] [Indexed: 12/18/2022]
Abstract
Introduction Synaptic loss is a robust and consistent pathology in Alzheimer's disease (AD) and the major structural correlate of cognitive impairment. Positron emission tomography (PET) imaging of synaptic vesicle glycoprotein 2A (SV2A) has emerged as a promising biomarker of synaptic density. Methods We measured SV2A binding in 34 participants with early AD and 19 cognitively normal (CN) participants using [11C]UCB‐J PET and a cerebellar reference region for calculation of the distribution volume ratio. Results We observed widespread reductions of SV2A binding in medial temporal and neocortical brain regions in early AD compared to CN participants. These reductions were largely maintained after correction for volume loss and were more extensive than decreases in gray matter volume. Conclusion We were able to measure widespread synaptic loss due to AD using [11C]UCB‐J PET. Future studies will continue to evaluate the utility of SV2A PET for tracking AD progression and for monitoring potential therapies.
Collapse
Affiliation(s)
- Adam P Mecca
- Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut.,Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut
| | - Ming-Kai Chen
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut.,Department of Neuroscience, Yale University School of Medicine, New Haven, Connecticut
| | - Ryan S O'Dell
- Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut.,Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut
| | - Mika Naganawa
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut
| | - Takuya Toyonaga
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut
| | - Tyler A Godek
- Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut.,Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut
| | - Joanna E Harris
- Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut.,Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut
| | - Hugh H Bartlett
- Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut.,Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut
| | - Wenzhen Zhao
- Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut.,Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut
| | - Nabeel B Nabulsi
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut
| | - Brent C Vander Wyk
- Program on Aging, Yale University School of Medicine, New Haven, Connecticut
| | - Pradeep Varma
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut
| | - Amy F T Arnsten
- Department of Neuroscience, Yale University School of Medicine, New Haven, Connecticut
| | - Yiyun Huang
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut
| | - Richard E Carson
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut
| | - Christopher H van Dyck
- Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut.,Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.,Department of Neuroscience, Yale University School of Medicine, New Haven, Connecticut.,Department of Neurology, Yale University School of Medicine, New Haven, Connecticut
| |
Collapse
|
10
|
Kemp EC, Ebner MK, Ramanan S, Godek TA, Pugh EA, Bartlett HH, McDonald JW, Mecca MC, van Dyck CH, Mecca AP. Statin Use and Risk of Cognitive Decline in the ADNI Cohort. Am J Geriatr Psychiatry 2020; 28:507-517. [PMID: 31806426 PMCID: PMC7170771 DOI: 10.1016/j.jagp.2019.11.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/22/2019] [Revised: 11/02/2019] [Accepted: 11/05/2019] [Indexed: 01/31/2023]
Abstract
OBJECTIVE To investigate associations between statin use and cognitive change, as well as diagnostic conversion, in individuals with cognitively normal (CN) status, mild cognitive impairment (MCI), and dementia due to Alzheimer disease (AD-dementia). METHODS A multicenter cohort study with 1629 adults 48 to 91 years old with CN status, early MCI (EMCI), late MCI (LMCI), or AD-dementia at baseline followed prospectively for 24 months. Statin use was assessed at baseline, and cognition was measured over time with a composite memory score, a composite executive function score, and a global cognition score (Alzheimer's Disease Assessment Scale). Conversion to a more impaired diagnostic category was determined by clinician assessment. Repeated measures linear mixed-effects models were used to evaluate associations between statin use and change in cognition over time. Cox proportional hazards models were used to evaluate associations between statin use and time to diagnostic conversion. All models were stratified by baseline diagnostic group. RESULTS Statin use was not associated with change in cognitive measures for CN, LMCI, or AD-dementia participants. Among EMCI participants, statin use was associated with a significantly slower rate of decline on the memory composite, but no other cognitive measure. Statin use was not associated with time to conversion for any diagnostic group. CONCLUSIONS This study did not support an association between statin use and diagnostic conversion but suggested a possible association between statin use and cognitive change in EMCI. Additional randomized clinical trials of statins may be warranted in the prodromal EMCI stage of AD.
Collapse
Affiliation(s)
- Emily C. Kemp
- Alzheimer’s Disease Research Unit, Yale University School of Medicine, One Church Street, 8th Floor, New Haven, CT, 06510, USA,Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA,Corresponding Author: Emily C. Kemp, B.S., One Church Street, 8th Floor, New Haven, CT 06510, (203) 764-8100 (phone), (203) 764-8111 (fax),
| | - Megan K. Ebner
- Alzheimer’s Disease Research Unit, Yale University School of Medicine, One Church Street, 8th Floor, New Haven, CT, 06510, USA,Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
| | - Srinath Ramanan
- Alzheimer’s Disease Research Unit, Yale University School of Medicine, One Church Street, 8th Floor, New Haven, CT, 06510, USA,Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
| | - Tyler A. Godek
- Alzheimer’s Disease Research Unit, Yale University School of Medicine, One Church Street, 8th Floor, New Haven, CT, 06510, USA,Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
| | - Erika A. Pugh
- Alzheimer’s Disease Research Unit, Yale University School of Medicine, One Church Street, 8th Floor, New Haven, CT, 06510, USA,Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
| | - Hugh H. Bartlett
- Alzheimer’s Disease Research Unit, Yale University School of Medicine, One Church Street, 8th Floor, New Haven, CT, 06510, USA,Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
| | - Julia W. McDonald
- Alzheimer’s Disease Research Unit, Yale University School of Medicine, One Church Street, 8th Floor, New Haven, CT, 06510, USA,Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
| | - Marcia C. Mecca
- Veterans Affairs Connecticut Healthcare System, 950 Campbell Ave, West Haven, CT, 06517, USA,Department of Internal Medicine, Geriatrics Section, and the Program on Aging, Yale University School of Medicine, New Haven, CT, USA
| | - Christopher H. van Dyck
- Alzheimer’s Disease Research Unit, Yale University School of Medicine, One Church Street, 8th Floor, New Haven, CT, 06510, USA,Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA,Department of Neuroscience, Yale University School of Medicine, New Haven, CT, USA,Department of Neurology, Yale University School of Medicine, New Haven, CT, USA
| | - Adam P. Mecca
- Alzheimer’s Disease Research Unit, Yale University School of Medicine, One Church Street, 8th Floor, New Haven, CT, 06510, USA,Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
| | | |
Collapse
|
11
|
Mecca AP, Chen MK, Godek TA, Harris JE, Bartlett HH, Toyonaga T, Naganawa M, Salardini A, Arnsten AF, Nabulsi NB, Lim K, Najafzadeh S, Ropchan JR, Huang Y, Carson RE, Strittmatter SM, van Dyck CH. IC-P-140: ASSOCIATION BETWEEN MGLUR5 AND SYNAPTIC DENSITY: A MULTI-TRACER STUDY IN HEALTHY AGING AND ALZHEIMER'S DISEASE. Alzheimers Dement 2019. [DOI: 10.1016/j.jalz.2019.06.4254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
12
|
Mecca AP, Chen MK, Naganawa M, Toyonaga T, Godek TA, Harris JE, Bartlett HH, Gallezot JD, Charil A, Nabulsi NB, Huang Y, Arnsten AF, Carson RE, van Dyck CH. P4-481: ASSOCIATION BETWEEN ENTORHINAL CORTICAL TAU ACCUMULATION AND HIPPOCAMPAL SYNAPTIC DENSITY IN OLDER INDIVIDUALS WITH NORMAL COGNITION AND EARLY ALZHEIMER'S DISEASE: PRELIMINARY EXPERIENCE. Alzheimers Dement 2019. [DOI: 10.1016/j.jalz.2019.08.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
13
|
Mecca AP, Chen MK, Godek TA, Harris JE, Bartlett HH, Toyonaga T, Naganawa M, Salardini A, Arnsten AF, Nabulsi NB, Lim K, Najafzadeh S, Ropchan JR, Huang Y, Carson RE, Strittmatter SM, van Dyck CH. P2-349: ASSOCIATION BETWEEN MGLUR5 AND SYNAPTIC DENSITY: A MULTI-TRACER STUDY OF HEALTHY AGING AND ALZHEIMER'S DISEASE. Alzheimers Dement 2019. [DOI: 10.1016/j.jalz.2019.06.2756] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
14
|
|
15
|
Affiliation(s)
- C D La Rue
- University of Michigan, Ann Arbor, Michigan
| | | |
Collapse
|
16
|
Affiliation(s)
- W W Tupper
- University of Michigan, Ann Arbor, Michigan
| | | |
Collapse
|
17
|
Tupper WW, Bartlett HH. A Comparison of the Wood Structure of Oenothera Stenomeres and its Tetraploid Mutation Gigas. Genetics 1916. [DOI: 10.1093/genetics/1.3.309a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
|
19
|
Bartlett HH. The Botanical Society of America. II. Science 1916; 43:322-9. [PMID: 17782281 DOI: 10.1126/science.43.1105.322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
20
|
Affiliation(s)
- W W Tupper
- University of Michigan, Ann Arbor, Michigan
| | | |
Collapse
|
21
|
Bartlett HH. THE BOTANICAL SOCIETY OF AMERICA. Science 1916; 43:285-92. [PMID: 17842707 DOI: 10.1126/science.43.1104.285-a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
22
|
|
23
|
|